Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $47.8M fell 20.5% year over year, in line with the -20.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at -2.4% a year.

Context

  • Depreciation & amortization amounted to 7.4% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.5% holds above the trailing-twelve-month pace of -20.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$47.8M+10.7% QoQ
Last fiscal yearDec 2025
$223.57M-5.3% YoY
LTMJun 2026
$194.29M-20.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.5%——
1 year-5.3%——
3-year CAGR-2.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
223.57M USD
Year-over-year change
-5.3%
4-year CAGR
-1.1%

Depreciation & Amortization vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.8% is the 10th highest of 11, against a peer median of -0.8%.
  • Depreciation & amortization amounts to 6.2% of revenue for AMRX, versus a peer median of 9.7%.
AMRX Competitors
Depreciation & Amortization for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹21.51B INR+12.7%+19.7%6.5%
VTRSViatris Inc.LTM Jun 2026$2.8B USD+1.6%-2.6%19.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B USD-5.6%-4.7%10.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$989M USD-3.3%-8.5%5.7%
PRGOPerrigo Company plcLTM Jun 2026$403.5M USD+22.7%-0.1%9.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M USD-20.8%-2.4%6.2%
EBSEmergent BioSolutions Inc.LTM Mar 2026$95.4M USD-8.8%-7.7%14.1%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.45M USD+17.8%+15.3%9.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$62.85M USD+7.5%+30.7%8.7%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$17M USD-26.1%+7.7%1.3%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$4.96M USD-16.3%-0.3%11.8%
Peer median (excluding AMRX) —-0.8%-0.2%9.7%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.